R-GemOx
Sponsors
The First Affiliated Hospital with Nanjing Medical University, Hutchmed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Ruijin Hospital
Conditions
DLBCL - Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaRelapsed and Refractory DLBCLRelapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
NCT01670370
Start: 2012-08-31End: 2019-12-31Target: 60Updated: 2019-02-15
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Active, not recruitingNCT06601504
Start: 2024-11-05End: 2026-11-12Updated: 2025-06-06
AZA Combined with R-GemOx for Elderly DLBCL Patients
Not yet recruitingNCT06778902
Start: 2025-02-01End: 2028-01-01Target: 80Updated: 2025-01-16
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not yet recruitingNCT07122609
Start: 2025-08-05End: 2027-08-15Target: 22Updated: 2025-08-14